Echocardiography, natriuretic peptides, and risk for incident heart failure in older adults: the Cardiovascular Health Study.

Pubmed ID: 22340818

Pubmed Central ID: PMC3293933

Journal: JACC. Cardiovascular imaging

Publication Date: Feb. 1, 2012

Affiliation: Emory Clinical Cardiovascular Research Institute, Emory University, Atlanta, Georgia, USA.

MeSH Terms: Humans, Male, Female, Aged, Risk Assessment, Heart Failure, Cardiomegaly, Ventricular Function, Left, Risk, Echocardiography, Peptide Fragments, Natriuretic Peptide, Brain, Biomarkers

Grants: AG-027058, AG-20098, HL080295, N01 HC-55222, N01-HC-75150, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, N01-HC-85239, N01 HC015103, N01 HC035129, N01 HC045133, N01HC55222, N01HC75150, N01HC85079, N01HC85086, R01 AG015928, R01 AG020098, R01 AG027058, R01 HL080295, U01 HL080295, AG-023269, U10 HL110302-01, P30 AG024827, R01 HL075366, UL1 RR025008, R56 AG020098

Authors: Butler J, Gottdiener JS, Kalogeropoulos AP, Georgiopoulou VV, deFilippi CR

Cite As: Kalogeropoulos AP, Georgiopoulou VV, deFilippi CR, Gottdiener JS, Butler J, Cardiovascular Health Study. Echocardiography, natriuretic peptides, and risk for incident heart failure in older adults: the Cardiovascular Health Study. JACC Cardiovasc Imaging 2012 Feb;5(2):131-40.

Studies:

Abstract

OBJECTIVES: This study sought to examine the potential utility of echocardiography and N-terminal pro-B-type natriuretic peptide (NT-proBNP) for heart failure (HF) risk stratification in concert with a validated clinical HF risk score in older adults. BACKGROUND: Without clinical guidance, echocardiography and natriuretic peptides have suboptimal test characteristics for population-wide HF risk stratification. However, the value of these tests has not been examined in concert with a clinical HF risk score. METHODS: We evaluated the improvement in 5-year HF risk prediction offered by adding an echocardiographic score and/or NT-proBNP levels to the clinical Health Aging and Body Composition (ABC) HF risk score (base model) in 3,752 participants of the CHS (Cardiovascular Health Study) (age 72.6 ± 5.4 years; 40.8% men; 86.5% white). The echocardiographic score was derived as the weighted sum of independent echocardiographic predictors of HF. We assessed changes in Bayesian information criterion (BIC), C index, integrated discrimination improvement (IDI), and net reclassification improvement (NRI). We examined also the weighted NRI across baseline HF risk categories under multiple scenarios of event versus nonevent weighting. RESULTS: Reduced left ventricular ejection fraction, abnormal E/A ratio, enlarged left atrium, and increased left ventricular mass were independent echocardiographic predictors of HF. Adding the echocardiographic score and NT-proBNP levels to the clinical model improved BIC (echocardiography: -43, NT-proBNP: -64.1, combined: -68.9; all p < 0.001) and C index (baseline: 0.746; echocardiography: +0.031, NT-proBNP: +0.027, combined: +0.043; all p < 0.01), and yielded robust IDI (echocardiography: 43.3%, NT-proBNP: 42.2%, combined: 61.7%; all p < 0.001), and NRI (based on Health ABC HF risk groups; echocardiography: 11.3%; NT-proBNP: 10.6%, combined: 16.3%; all p < 0.01). Participants at intermediate risk by the clinical model (5% to 20% 5-yr HF risk; 35.7% of the cohort) derived the most reclassification benefit. Echocardiography yielded modest reclassification when used sequentially after NT-proBNP. CONCLUSIONS: In older adults, echocardiography and NT-proBNP offer significant HF risk reclassification over a clinical prediction model, especially for intermediate-risk individuals.